BIAF (bioAffinity Technologies Inc.) רווח נקי למניה (EPS TTM)

bioAffinity Technologies (BIAF) is developing the Physiocist AI system for rapid sputum analysis, creating a closed diagnostic loop. The 12-month net income per share trend allows for an assessment of this model's scalability, where -38.35 determines the latest valuation metric. A stable team of oncologist-developers and the company's status as a recognized expert in non-invasive screening provide bioAffinity Technologies with long-term growth potential.

Conservative asset selection requires an analysis of the actual return on each share of capital. This indicator calculates the total annual net income divided by the total number of shares, excluding the volatility of quarterly reports. For bioAffinity Technologies (BIAF), this parameter is critical, as challenges with test implementation and insurance coverage directly impact profitability. The trailing twelve months (TTM) net income per share trend reflects the fundamental stability of the business.